Phase 2 study of TLK286 [canfosfamide; TELCYTA; Telik] in platinum resistant advanced epithelial ovarian cancer.
Phase of Trial: Phase II
Latest Information Update: 22 Jul 2011
At a glance
- Drugs Canfosfamide (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 22 Jul 2011 Actual end date (Jul 2005) added as reported by ClinicalTrials.gov.
- 22 Jul 2011 Actual initiation date (Jun 2001) added as reported by ClinicalTrials.gov.
- 14 Jan 2008 Status change from in progress to completed